NLS Pharmaceutics Launches Preclinical Program for Mazindol ER in Fentanyl Dependence Treatment

Mazindol ER: A Potential Non-Opioid Alternative for Fentanyl Addiction The Current Opioid Crisis The Centers for Disease Control and Prevention (CDC) recently reported that there were 105,007 drug overdose deaths, with 90% involving synthetic opioids such as fentanyl. This staggering statistic highlights the urgent need for alternative treatments to address opioid addiction. Mazindol ER: An…

Read More

Vashtra’s Single Step Forward: Understanding the Implications of One Swallow Medication

Viatris Inc.: A Disappointing Performance and the Challenges Ahead Viatris Inc. (VTRS), the newly formed generic and branded specialty pharmaceuticals company, recently reported earnings for the second quarter of 2023. The results came in below analysts’ estimates, raising concerns among investors and analysts. In this blog post, we will discuss the reasons behind Viatris’ disappointing…

Read More

Workiva’s Q4 Earnings: A Perfect Match to Estimates – A Tale of Numbers and Accuracy

Workiva’s Quarterly Earnings: A Peek Behind the Numbers Workiva (WK), the leading provider of Wdesk, a cloud-based platform for data collaboration, reporting, and compliance, recently announced its quarterly earnings for the period ending March 31, 2023. Let’s dive in and explore the details. The Numbers The company reported earnings of $0.33 per share, which was…

Read More

SJW Corporation (SJW): Analysts Anticipate Decrease in Earnings – Key Factors to Watch

SJW (SJW) Falling Short of Earnings Expectations: A Closer Look Investors and analysts closely monitor the earnings reports of publicly-traded companies, as they provide valuable insights into a company’s financial health and future prospects. One such company that has recently come under the radar is SJW Group (SJW), a leading provider of water utility services…

Read More